Axon Enterprise — Feb 24, 2026 release

This operational metric tracks total unfulfilled contracted bookings for products and services, including remaining performance obligations as well as contracts with certain ter mination or other clauses that are not otherwise included in remaining performance obligations. We expect to fulfill between 20% and 25% of this balance over the next 12 months and generally expect the remainder to be fulfilled over the following ten years. Outlook & Target Model The following forward-looking statements reflect Axon’s expectations as of February 24, 2026 and are subject to risks and uncertainties. Please refer to “Forward-Looking Statements” below for additional information. Full Year 2026 Guidance • Revenue growth of 27% to 30% year over year • Adjusted EBITDA margin of 25.5% • Stock-based compensation expense of $590 million to $620 million • Capital expenditures in the range of $185 million to $215 million Full-year 2026 stock-based compensation expense includes approxim ately $230 million re lated to the broad-based Employee XSP and the CEO Performance Award, primarily within SG&A and R&D. These performance-based incentive programs are tied to stock price, operational, and time-based requirements, and include seven substantially equal tranches. 2026 capital expenditure plans include long-term R&D investment projects, continued capacity expansion, global facility build-outs and new product development costs. Expected capital expenditures do not include costs related to investments in a new headq